Aegerion Pharmaceuticals: UK's Amryt Pharma unites lomitapide franchise with Aegerion deal
Britain's Amryt Pharma has agreed to buy Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, in a deal that reunites the franchise for lomitapide, a treatment for patients with a rare cholesterol disorder.
Read full article »
CEO
Aegerion is a Massachusetts-based biopharmaceutical company that develops and commercializes novel therapies for the treatment of severe and rare diseases.
Read more